Notes to the Consolidated Financial Statements continued 21.
Borrowings 2018 2017 m m Current liabilities: Bank loans 1.2 1.0 1.2 1.0 Non-current liabilities: Bank loans 293.3 180.6 Arrangement fees netted off 3.4 0.4 289.9 180.2 Total borrowings 291.1 181.2 In July 2017 the Group replaced its existing facility of 205.0 million with a multi-currency revolving credit facility of 235.0 million, with an accordion of 125.0 million until 2022.
During the year the termination date was extended to 2023 with the possibility of further extending to 2024.
At the year end 157.7 million was drawn down against this facility.
The facility is not secured on any specific assets of the Group but is supported by a joint and several cross guarantee structure.
Interest will be charged at a minimum of 1.3% over LIBOR and at a maximum of 2.2% over LIBOR, dependent upon the Leverage the ration of Total Net Debt to Adjusted EBITDA of the Group.
At 30 June 2018, interest being charged on this facility is 1.5% above LIBOR.
All covenants were met during the year ended 30 June 2018.
On replacement of the existing facility, arrangement fees of 0.4 million were written off as non-underlying in relation to this facility.
In January 2018 the Group entered into a new multi-currency Term Loan facility of 350.0 million until 31 December 2020.
At the year end 132.9 million was drawn against this facility.
Interest will be charged at a minimum of 1.1% over LIBOR and at a maximum of 2.0% over LIBOR, dependent upon the Leverage the ratio of Total Net Debt to Adjusted EBITDA of the Group.
Arrangement fees of 3.9 million were incurred on the new facilities during the year, these are being released to the income statement over the life of the facilities.
Genera also has borrowing facilities of 6.9 million, of which 3.9 million was drawn down at 30 June 2018.
The maturity of the bank loans and overdrafts is as follows: 2018 2017 m m Payable: Within one year 1.2 1.0 Between one and two years 1.3 1.2 Between two and five years 292.0 179.4 294.5 181.6 Further information on the interest profile of borrowings is shown in note 24.
138 Dechra Pharmaceuticals PLC Annual Report and Accounts for the year ended 30 June 2018 www.
